about
Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trialAn efficient RNA-cleaving DNA enzyme that synchronizes catalysis with fluorescence signaling.Efficacy and safety of mesenchymal stromal cells in preclinical models of acute lung injury: a systematic review protocol.Lack of elevation in plasma levels of pro-inflammatory cytokines in common rodent models of pulmonary arterial hypertension: questions of construct validity for human patientsThe Devil Is in the Details: Incomplete Reporting in Preclinical Animal Research.Targeted delivery of genes to endothelial cells and cell- and gene-based therapy in pulmonary vascular diseases.The Immunomodulatory and Therapeutic Effects of Mesenchymal Stromal Cells for Acute Lung Injury and Sepsis.DJ-1/PARK7 Impairs Bacterial Clearance in Sepsis.Advances in Stem Cell and Cell-Based Gene Therapy Approaches for Experimental Acute Lung Injury: A Review of Preclinical Studies.Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis.Cell-based angiopoietin-1 gene therapy for acute lung injury.High circulating angiopoietin-2 levels exacerbate pulmonary inflammation but not vascular leak or mortality in endotoxin-induced lung injury in mice.Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial.Effects of mesenchymal stem cell therapy on the time course of pulmonary remodeling depend on the etiology of lung injury in mice.Occlusive lung arterial lesions in endothelial-targeted, fas-induced apoptosis transgenic mice.Assemblage of signaling DNA enzymes with intriguing metal-ion specificities and pH dependencesAngiopoietin and vascular remodeling: the data at face valueEfficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodellingEffects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock PatientsThawed Mesenchymal Stem Cell Product Shows Comparable Immunomodulatory Potency to Cultured Cells In Vitro and in Polymicrobial Septic AnimalsClinical comparison between neuroendocrine and endometrioid type carcinoma of the uterine corpus
P50
Q28587757-831F8160-8A7E-47B6-8250-A23482334E6DQ30878974-A0178AC8-E72A-4057-9BA2-B5A6B823E96CQ33714606-49DD6607-E6CD-42E4-AF16-C248D5D822BDQ33788533-BE6F2DA5-B63D-466B-8054-DB1F2C660BEAQ36195278-8A2B8BC4-5DC3-4E3E-B621-9D886EE8D76FQ38165146-9D824E13-592A-48AF-980B-76B2AE4E894FQ38442767-2432C0DC-790C-4CD5-91AD-1A508F16D783Q38741406-A34DAF3B-5675-4C3F-AA76-15D6918E440EQ38830673-06AB3467-0EC7-4213-9D04-652C72DD81AAQ44486370-BBEDC4F6-04EE-496D-B4C0-E8CF38AD4448Q45866244-37AB7106-D662-45C4-AFF4-3511A37E3011Q47744102-0C5EE8F6-4BE5-4682-AD9F-432C20C707F0Q50272927-402CCA63-5198-47D8-97BD-D2E73F0C1DB7Q50804069-C3FA7B11-787F-4A9E-829B-69BCB2378E09Q51640257-8CEC410B-985A-44CE-BD87-145CCC2369C0Q73542083-1BD49408-8CC7-4619-ADB2-BFF50E277AC8Q83323480-2BB438D2-874B-4625-A21D-D00C25A9C8E0Q90883399-5733E9B7-DE73-4E18-A1C2-676192880815Q91348189-8A142B55-CF67-4ED5-9E73-0C3170B3FA5FQ91620358-1305E6DE-AB66-40FC-9304-BFE7FBEF3CE6Q91909354-5100DE20-9B65-4FFD-9149-7D54CDC15707
P50
description
researcher
@en
name
Shirley H J Mei
@en
Shirley H J Mei
@nl
type
label
Shirley H J Mei
@en
Shirley H J Mei
@nl
prefLabel
Shirley H J Mei
@en
Shirley H J Mei
@nl
P106
P31
P496
0000-0003-4727-1177